Stopping schizophrenia before it starts?
January 27, 2010 by admin · Leave a Comment
Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University Read more
Team finds childhood clues to adult schizophrenia
January 20, 2010 by admin · Leave a Comment
Contact: Karl Leif Bates
karl.bates@duke.edu
919-681-8054
Duke University
DURHAM, N.C. Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.
Estrogen in the fight against schizophrenia
January 19, 2010 by admin · Leave a Comment
Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University Read more
Blood test for schizophrenia could be ready this year
January 19, 2010 by admin · Leave a Comment
Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
A blood test for diagnosing schizophrenia the most serious form of mental illness could be available this year, according to an article in the current issue of Chemical & Engineering News, ACS’ weekly newsmagazine. The disorder, with symptoms that can include hallucinations and delusional thoughts, affects more than two million people in the United States and millions more worldwide.
Schizophrenia mouse model should improve understanding and treatment of the disorder
December 27, 2009 by admin · Leave a Comment
Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
AUGUSTA, Ga. Scientists have created what appears to be a schizophrenic mouse by reducing the inhibition of brain cells involved in complex reasoning and decisions about appropriate social behavior.
Faulty ‘wiring’ in the brain triggers onset of schizophrenia
October 26, 2009 by admin · Leave a Comment
A new study by researchers at the Institute of Psychiatry (IoP), King’s College London has discovered abnormalities in the white matter of the brain that seem to be critical for the timing of schizophrenia. The study, led by Professor Phillip McGuire and Dr Sophia Frangou, has been published in this month’s edition of the British Journal of Psychiatry.
Treatment for epilepsy is a possible culprit for development of schizophrenia
October 21, 2009 by admin · Leave a Comment
Researchers say antiepilectic drug treatments administered when the brain is developing appear to trigger schizophrenia-like behavior in animal models. In humans, having a history of seizures in infancy is a significant risk factor for development of schizophrenia later in life, but it is not known whether the elevated risk is due to seizures themselves, or from side effects antiepileptic drug (AED) treatment.
Brain defect implicated in early schizophrenia
September 7, 2009 by admin · Leave a Comment
Findings may help predict disease progression and provide opportunities for more targeted drug development to block mechanism
NEW YORK - In the first functional magnetic resonance imaging (fMRI) study of its kind, neurologists and psychiatrists at Columbia University have identified an area of the brain involved in the earliest stages of schizophrenia and related psychotic disorders.
Animal model for schizophrenia identifies a new approach for treating cognitive impairments
June 9, 2009 by admin · Leave a Comment
Researchers have been seeking a safe and effective way to treat cognitive impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) glutamate receptors. Functional deficits in NMDA receptors may contribute to the underlying neurobiology of this disorder. The first generation of studies trying to stimulate NMDA receptors administered large amounts of substances, like glycine or D-serine, which indirectly enhance NMDA receptor function. While there were some positive reports of efficacy, findings across studies were more inconsistent than was hoped.
First compound for receptors in schizophrenia and Alzheimer’s holds promise
April 21, 2009 by admin · Leave a Comment
For almost 20 years, pharmacological companies have known that certain compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer’s disease (AD).
